Sarika Sharma, MD
Cardiology · Rochelle Park, NJNPI 1821042771
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 629 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,012 and has fallen 50.5% since, to $995 in 2025. Among cardiology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 629 payments — averaging $14.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- AstraZeneca$1K
- Kowa Pharmaceuticals America, Inc.$942
- Novartis$922
- Novo Nordisk$801
- Bayer$572
- plus $3K from 34 others
What the payments were for
- Food & beverage$8,86798%
- Education$1682%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,034 in reported general payments places this provider in the 90th percentile of 31 cardiology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 207 | $158,829 |
| OzempicSemaglutide | 116 | $124,499 |
| MounjaroTirzepatide | 60 | $76,589 |
| EntrestoSacubitril/Valsartan | 83 | $65,373 |
| Metformin Er GastricMetformin Hcl | 21 | $58,093 |
| JardianceEmpagliflozin | 63 | $56,545 |
| JanuviaSitagliptin Phosphate | 39 | $51,873 |
| JanumetSitagliptin Phos/Metformin Hcl | 24 | $36,311 |
| Tresiba Flextouch U-100Insulin Degludec | 66 | $35,986 |
| FarxigaDapagliflozin Propanediol | 29 | $35,389 |
| TradjentaLinagliptin | 40 | $33,211 |
| XareltoRivaroxaban | 26 | $30,657 |
| Repatha SureclickEvolocumab | 38 | $29,022 |
| EdarbiAzilsartan Medoxomil | 31 | $15,527 |
| KerendiaFinerenone | 18 | $14,938 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $428 | $158,829207 claims |
| Novo NordiskOzempic | $801 | $124,499116 claims |
| Boehringer IngelheimJardiance, Tradjenta | $222 | $89,757103 claims |
| Lilly USA, LLCMounjaro | $100 | $76,58960 claims |
| NovartisEntresto | $922 | $65,37383 claims |
| AstraZenecaFarxiga | $1,003 | $35,38929 claims |
| Johnson & JohnsonXarelto | $460 | $30,65726 claims |
| Arbor Pharmaceuticals, Inc.Edarbi, Edarbyclor | $384 | $23,68851 claims |
| GSKBreo Ellipta, Anoro Ellipta | $55 | $15,18229 claims |
| BayerKerendia | $572 | $14,93818 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $31 | $2,45456 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 31 cardiology providers in New Jersey.
Other cardiology in Rochelle Park
- Michael SchwarzRutherford$40K
- Beverly DemchukOcean$12K
- Lei XuBrown Hills$10K
- Vasant Paul KateBrick$7K
- Pragnesh GadhviUnion City$7K
- Ebrahim IssaTeaneck$5K
- Ricardo CalvoEdison$5K
- Marc ColmerNeptune$5K
- Ian MolkEdison$4K
- Tanveer AhmadBrick$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.